The Use of IO Doublet in PD-L1-Negative NSCLC

David Carbone

How do I Recognize and Treat the VEXAS Syndrome?

Cleveland Clinic Rheumatology

P. Grayson

2024 Intervention Selection & Sequencing in Early Stage NSCLC

Total Health

J. Porter

Year in Review: Lung Cancer

Balazs Halmos

ASCO® 2024 Lung Cancer Highlights: Top Abstracts Including BEAT-SC, …

2024 ASCO® Annual Meeting Insights Hub

B. Halmos

Updates in the Management of NSCLC: Systemic Therapy Year in Review

Total Health

W. Iams

Hyperprogression in Cancer Treated With Immunotherapy

Northwestern Medicine Oncology and Hematology

Y. Chae

Mediastinal Staging of Lung Cancer

MI&T Congressi

R. Trisolini

Recent NSCLC Updates Including PAPILLON, CHECKMATE 77T, and KEYNOTE-…

ecancer

L. Raez

2024 Updates on the Fast-Changing NSCLC Landscape

Total Health

R. Osarogiagbon

ASCO® 2024 Lung Cancer Roundtable: Advances in NSCLC

ecancer

E. Felip, A. Spira, A. Passaro, A. Addeo

Multidisciplinary Panel Discussion: New Treatment Options for Surgic…

David Carbone

B. Stiles

Year in Review: Precision Medicine

Vivek Subbiah

Controversies in NSCLC: Neoadjuvant vs. Adjuvant IO in Early Stage D…

Luis Raez

Duration of Immunotherapy Beyond 2 Years for Patients With Advanced …

IASLC Targeted Therapies of Lung Cancer 2023 Conference Coverage

E. Rodriguez

Endocrine Adverse Events From Checkpoint Inhibitors

Yale Cancer Center

K. Herold

Checkpoint Inhibitors, Arthritis and Other Autoimmune Triggers

West Virginia State Rheumatology Society

J. Bustamante

WCLC 2024 Insights: Adjuvant vs. Neoadjuvant vs. Peri-Operative Ther…

Insights from 2024 WCLC

J. Von Der Thusen

PACIFIC Trial 5-Year OS Data: Clinical Implications in NSCLC

John Conibear

World Lung Cancer Day: Key Insights and Advances in Lung Cancer Trea…

Oncology Data Advisor

S. Kareff, B. Sandy, M. Vojnic